10-Q: Stemtech Corporation Reports Second Quarter 2024 Results with Increased Revenue and Ongoing Financial Challenges

Stemtech Corporation's Q2 2024 results show a revenue increase compared to the same period last year, but the company continues to face significant financial challenges and operating losses.

Summary

• Stemtech Corporation reported a net loss of $2,204,716 for the six months ended June 30, 2024, compared to a net loss of $2,527,890 for the same period in 2023.
• The company's revenue increased to $2,708,370 for the first six months of 2024, up from $2,261,467 in the first six months of 2023.
• Operating expenses for the six months ended June 30, 2024, totaled $3,733,944, compared to $3,989,075 for the same period in 2023.
• The company's accumulated deficit stood at $29,263,992 as of June 30, 2024.
• Stemtech's cash balance increased to $259,570 as of June 30, 2024, from $114,166 at the end of 2023.
• The company has significant liabilities, including $4,288,873 in accounts payable and accrued expenses, $1,883,526 in notes payable, and $1,939,548 in convertible debentures as of June 30, 2024.
• The company's total assets were $3,690,246 and total liabilities were $8,618,696 as of June 30, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is revenue growth, the significant losses, accumulated deficit, and going concern issues weigh heavily on the sentiment. The company's reliance on debt and the need for further capital raises also contribute to a negative outlook.

Positives

• The company experienced an increase in net sales for the six months ended June 30, 2024, compared to the same period in 2023.
• Gross profit also increased for the six months ended June 30, 2024, compared to the same period in 2023.
• The company's cash balance improved from the end of 2023 to June 30, 2024.

Negatives

• The company continues to operate at a loss, with a net loss of $2,204,716 for the six months ended June 30, 2024.
• The company has a significant accumulated deficit of $29,263,992 as of June 30, 2024.
• Total liabilities significantly exceed total assets, indicating a precarious financial position.
• The company has substantial debt obligations, including notes payable and convertible debentures.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise capital and generate sufficient revenue.
• The company's cash position may not be sufficient to support its daily operations.
• The company faces risks related to market acceptance of its products, competition, and regulatory developments.
• The company's reliance on factoring agreements for working capital could be a risk if these arrangements become unavailable.
• The company has a history of losses and may not achieve profitability.
• The company's future financing through equity investments is likely to be dilutive to existing stockholders.

Future Outlook

The company expects that working capital requirements will continue to be funded through a combination of existing funds and further issuances of securities, and anticipates additional increases in operating expenses and capital expenditures relating to inventory, development, marketing, and IT website development.

Management Comments

• Management believes that given the cash on hand and working expenditures, they can reinvigorate sales to be more consistent with the company's previous revenue historically.
• Management anticipates additional increases in operating expenses and capital expenditures relating to inventory, development, marketing, and IT website development.
• Management believes that the resolution of the legal matter will not have a material adverse impact on the company's consolidated financial position or consolidated results of operations.

Industry Context

Stemtech operates in the dietary supplements and network marketing industry, focusing on stem cell nutrition. The company is positioned to benefit from the growing awareness of stem cell benefits and the increasing global market for stem cell therapies and related products. The company's direct-to-consumer and independent business partner model aligns with current trends in e-commerce and the gig economy.

Comparison to Industry Standards

• Stemtech's revenue growth of approximately 20% year-over-year is a positive sign, but it is difficult to compare directly to industry standards without more specific data on comparable companies in the stem cell nutrition sector.
• The company's significant operating losses and accumulated deficit are concerning and indicate that it is not yet performing at the level of established, profitable companies in the broader dietary supplement industry.
• The company's reliance on debt financing and factoring arrangements is not uncommon for early-stage companies, but it does highlight the need for improved cash flow and profitability.
• Compared to larger, more established network marketing companies, Stemtech's financial position is weaker, with a higher debt-to-asset ratio and ongoing losses.
• The company's focus on a niche market (stem cell nutrition) may provide a competitive advantage, but it also carries the risk of limited market size and acceptance compared to more mainstream supplement categories.

Management Changes

Legal Proceedings

• The company is involved in a legal proceeding with its former CEO, alleging unpaid salary and vacation time, with a claim of $267,000. The company has counter-sued the plaintiff and deems the matter non-meritorious.

Related Party Transactions

• The company has engaged in various related party transactions, including loans from officers and directors, stock issuances for services, and payments for accrued salaries and fees.
• On February 15, 2024, John W. Meyer, President & COO of the Company, made a loan of $5,000.00 to the company.
• On March 19, 2024, the Company issued 900,000 shares to the Chief Financial Officer as stock compensation in lieu of cash for services for a fair value of $0.03 per share for a total of $27,000.
• On March 19, 2024, the Company issued 1,000,000 shares to five directors for a total of 5,000,000 shares at a fair value of $0.03 per share or a total of $150,000.
• The company amortized $439,054 of previous stock compensation granted to its Chairman and CEO that is being amortized over 82 months.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity issuances and potential loss of investment due to the company's financial challenges.
• Employees may be impacted by cost-cutting measures and the company's uncertain financial future.
• Customers may experience disruptions in product availability due to inventory issues.
• Suppliers and creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to continue to implement its business plan and generate sufficient revenue.
• The company intends to raise additional funds through private or public offerings.
• The company plans to continue to develop and market its stem cell nutrition products.
• The company plans to grow its independent business partner network.

Key Dates

Keywords

Stemtech, financial results, quarterly report, stem cell nutrition, net sales, net loss, operating expenses, convertible debentures, notes payable, going concern, financial statements, direct sales, independent business partners